Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: DPH1 (ImmuneEditome ID:1801)

1. Gene summary of enriched editing regions for DPH1

Gene summary

Gene information	Gene symbol	DPH1
	Gene ID	1801
	GeneSynonyms	DEDSSH\|DPH2L\|DPH2L1\|OVCA1
	GeneCytomap	17p13.3
	GeneType	protein-coding
	GeneDescription	2-(3-amino-3-carboxypropyl)histidine synthase subunit 1\|DPH-like 1\|DPH1 homolog\|DPH2-like 1\|S-adenosyl-L-methionine:L-histidine 3-amino-3-carboxypropyltransferase 1\|candidate tumor suppressor in ovarian cancer 1\|diphthamide biosynthesis protein 1\|diphthamide biosynthesis protein 2 homolog-like 1\|diphtheria toxin resistance protein 1\|diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 1\|ovarian cancer-associated gene 1 protein\|ovarian tumor suppressor candidate 1
	GeneModificationdate	20230329
	UniprotID	Q9BZG8;V9GYC0;K7EQQ6;V9GYS2;I3L1H5;A0A6Q8JGF9
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:2036918-2039688:+	ENST00000263083.9	ENSG00000108963.16	DPH1	exonic	AluY,MIRb,MER1B,AluSc8,MIR3,AluJb	chr17:2036918-2039688:+.alignment
chr17:2036918-2039688:+	ENST00000570477.4	ENSG00000108963.16	DPH1	exonic	AluY,MIRb,MER1B,AluSc8,MIR3,AluJb	chr17:2036918-2039688:+.alignment
chr17:2036918-2039688:+	ENST00000571418.4	ENSG00000108963.16	DPH1	exonic	AluY,MIRb,MER1B,AluSc8,MIR3,AluJb	chr17:2036918-2039688:+.alignment
chr17:2036918-2039688:+	ENST00000575667.4	ENSG00000108963.16	DPH1	exonic	AluY,MIRb,MER1B,AluSc8,MIR3,AluJb	chr17:2036918-2039688:+.alignment

Top

2. Tumor-specific enriched editing regions for DPH1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for DPH1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for DPH1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000108963.16,DPH1

ESCA

EAG

ENSG00000155659.10

chrX

66022840:66022862:66021737:66022166:66021737:66022500

0.3139

2.6241e-02

2.2624e-05

0.4160

DKC1;EIF4A3;ELAVL1;FBL;FUS;TAF15;UPF1

VSIG4

T_cells_CD4_naive

More results

Top

5. Enriched editing regions and immune infiltration for DPH1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:2036918-2039688:+	BLCA	EER	NK_cells_activated	2.9127e-02	-0.3057
ENSG00000108963.16,DPH1	BLCA	EAG	NK_cells_activated	2.9127e-02	-0.3057
chr17:2036918-2039688:+	BRCA	EER	Eosinophils	1.0022e-02	0.1859
ENSG00000108963.16,DPH1	BRCA	EAG	Eosinophils	1.0022e-02	0.1859
ENSG00000108963.16,DPH1	ESCA	EAG	T_cells_CD4_naive	1.0015e-02	0.2202
chr17:2036918-2039688:+	GBM	EER	T_cells_gamma_delta	1.2890e-02	0.2841
ENSG00000108963.16,DPH1	GBM	EAG	T_cells_gamma_delta	1.2890e-02	0.2841
chr17:2036918-2039688:+	KIRC	EER	T_cells_gamma_delta	1.6796e-02	0.2055
ENSG00000108963.16,DPH1	KIRC	EAG	T_cells_gamma_delta	1.6796e-02	0.2055
chr17:2036918-2039688:+	LAML	EER	T_cells_CD4_naive	2.3789e-02	-0.2089
ENSG00000108963.16,DPH1	LAML	EAG	T_cells_CD4_naive	2.3789e-02	-0.2089
chr17:2036918-2039688:+	LUAD	EER	T_cells_follicular_helper	4.6339e-02	0.2356
ENSG00000108963.16,DPH1	LUAD	EAG	T_cells_follicular_helper	4.6339e-02	0.2356
chr17:2036918-2039688:+	LUSC	EER	Eosinophils	3.5809e-04	0.4233
ENSG00000108963.16,DPH1	LUSC	EAG	Eosinophils	3.5809e-04	0.4233
chr17:2036918-2039688:+	OV	EER	T_cells_CD4_naive	1.0962e-02	0.1800
ENSG00000108963.16,DPH1	OV	EAG	T_cells_CD4_naive	1.0962e-02	0.1800
chr17:2036918-2039688:+	PRAD	EER	NK_cells_activated	1.4947e-02	0.1939
ENSG00000108963.16,DPH1	PRAD	EAG	NK_cells_activated	1.4947e-02	0.1939
chr17:2036918-2039688:+	SARC	EER	T_cells_CD4_memory_activated	1.1061e-02	0.5091
ENSG00000108963.16,DPH1	SARC	EAG	T_cells_CD4_memory_activated	1.1061e-02	0.5091
chr17:2036918-2039688:+	SKCM	EER	Plasma_cells	1.3996e-02	0.2475
ENSG00000108963.16,DPH1	SKCM	EAG	Plasma_cells	1.3996e-02	0.2475
chr17:2036918-2039688:+	STAD	EER	Macrophages_M1	4.7611e-03	-0.2040
ENSG00000108963.16,DPH1	STAD	EAG	Macrophages_M1	4.7611e-03	-0.2040

Top

6. Enriched editing regions and immune gene sets for DPH1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000108963.16,DPH1	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	1.6699e-02	0.2049
chr17:2036918-2039688:+	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	7.7302e-06	0.4881
ENSG00000108963.16,DPH1	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	7.7302e-06	0.4881
chr17:2036918-2039688:+	LAML	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	8.0531e-04	0.3056
ENSG00000108963.16,DPH1	LAML	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	8.0531e-04	0.3056
chr17:2036918-2039688:+	LUAD	GSVA_HALLMARK_G2M_CHECKPOINT	EER	2.4055e-02	0.2658
ENSG00000108963.16,DPH1	LUAD	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	2.4055e-02	0.2658
chr17:2036918-2039688:+	LUSC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	5.5279e-03	0.3354
ENSG00000108963.16,DPH1	LUSC	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	5.5279e-03	0.3354
chr17:2036918-2039688:+	PAAD	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	3.2889e-02	0.3972
ENSG00000108963.16,DPH1	PAAD	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	3.2889e-02	0.3972
chr17:2036918-2039688:+	PCPG	GSVA_HALLMARK_DNA_REPAIR	EER	3.2585e-02	-0.2787
ENSG00000108963.16,DPH1	PCPG	GSVA_HALLMARK_DNA_REPAIR	EAG	3.2585e-02	-0.2787
ENSG00000108963.16,DPH1	PRAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	4.8798e-02	-0.1575
chr17:2036918-2039688:+	PRAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	4.8798e-02	-0.1575
ENSG00000108963.16,DPH1	SKCM	GSVA_HALLMARK_MYOGENESIS	EAG	1.5784e-02	0.2433
chr17:2036918-2039688:+	SKCM	GSVA_HALLMARK_MYOGENESIS	EER	1.5784e-02	0.2433
chr17:2036918-2039688:+	STAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	4.9207e-03	0.2032
ENSG00000108963.16,DPH1	STAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	4.9207e-03	0.2032
chr17:2036918-2039688:+	TGCT	GSVA_HALLMARK_MTORC1_SIGNALING	EER	3.1059e-02	0.3293
ENSG00000108963.16,DPH1	TGCT	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	3.1059e-02	0.3293

Top

7. Enriched editing regions and drugs for DPH1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr17:2036918-2039688:+	BLCA	Cytarabine	EER	8.6256e-03	0.3641
ENSG00000108963.16,DPH1	BLCA	Cytarabine	EAG	8.6256e-03	0.3641
chr17:2036918-2039688:+	BRCA	JNK.Inhibitor.VIII	EER	3.9197e-02	0.1498
ENSG00000108963.16,DPH1	BRCA	JNK.Inhibitor.VIII	EAG	3.9197e-02	0.1498
ENSG00000108963.16,DPH1	ESCA	Gefitinib	EAG	7.6916e-04	-0.2861
ENSG00000108963.16,DPH1	GBM	Bosutinib	EAG	7.6958e-03	0.3035
chr17:2036918-2039688:+	GBM	Bosutinib	EER	7.6958e-03	0.3035
chr17:2036918-2039688:+	KIRC	Bleomycin	EER	2.4849e-03	-0.2583
ENSG00000108963.16,DPH1	KIRC	Bleomycin	EAG	2.4849e-03	-0.2583
chr17:2036918-2039688:+	KIRP	Embelin	EER	1.3204e-02	0.2831
ENSG00000108963.16,DPH1	KIRP	Embelin	EAG	1.3204e-02	0.2831
chr17:2036918-2039688:+	LAML	AZD8055	EER	2.2696e-02	0.2105
ENSG00000108963.16,DPH1	LAML	AZD8055	EAG	2.2696e-02	0.2105
ENSG00000108963.16,DPH1	LGG	JNK.Inhibitor.VIII	EAG	1.3791e-02	-0.1435
chr17:2036918-2039688:+	LGG	JNK.Inhibitor.VIII	EER	1.3791e-02	-0.1435
chr17:2036918-2039688:+	LUSC	EHT.1864	EER	4.9366e-02	0.2411
ENSG00000108963.16,DPH1	LUSC	EHT.1864	EAG	4.9366e-02	0.2411
chr17:2036918-2039688:+	OV	Bortezomib	EER	1.0538e-02	-0.1810
ENSG00000108963.16,DPH1	OV	Bortezomib	EAG	1.0538e-02	-0.1810
chr17:2036918-2039688:+	PAAD	BMS.536924	EER	5.2849e-03	0.5042
ENSG00000108963.16,DPH1	PAAD	BMS.536924	EAG	5.2849e-03	0.5042
ENSG00000108963.16,DPH1	PCPG	EHT.1864	EAG	7.5111e-03	0.3447
chr17:2036918-2039688:+	PCPG	EHT.1864	EER	7.5111e-03	0.3447
chr17:2036918-2039688:+	PRAD	GSK.650394	EER	2.3284e-02	-0.1810
ENSG00000108963.16,DPH1	PRAD	GSK.650394	EAG	2.3284e-02	-0.1810
ENSG00000108963.16,DPH1	SARC	AZD7762	EAG	1.5366e-03	-0.6104
chr17:2036918-2039688:+	SARC	AZD7762	EER	1.5366e-03	-0.6104
ENSG00000108963.16,DPH1	SKCM	BMS.536924	EAG	2.6583e-02	-0.2252
chr17:2036918-2039688:+	SKCM	BMS.536924	EER	2.6583e-02	-0.2252
chr17:2036918-2039688:+	STAD	Erlotinib	EER	3.5603e-02	0.1530
ENSG00000108963.16,DPH1	STAD	Erlotinib	EAG	3.5603e-02	0.1530
ENSG00000108963.16,DPH1	TGCT	Cisplatin	EAG	3.9586e-02	-0.3151
chr17:2036918-2039688:+	TGCT	Cisplatin	EER	3.9586e-02	-0.3151

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType